Oryzon Genomics reaffirms its commitment to the research in neurodegenerative diseases on the World Multiple Sclerosis Day

MADRID, SPAIN and CAMBRIDGE MA.

• The company has a drug, ORY-2001, in Phase IIa clinical trial in Multiple Sclerosis

Today, 30th May, is World Multiple Sclerosis Day 2018. Oryzon Genomics, a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, is developing ORY-2001 for the treatment of Central Nervous System (CNS) diseases, like Multiple Sclerosis (MS). At the end of October 2017 Oryzon received the approval from the Spanish Medicines Agency to start a Phase IIa clinical trial with ORY-2001 in MS, which is currently ongoing, with patient recruitment having started in January 2018. This study is a randomised, double-blind, 36 weeks study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS). At the international conference on MS ACTRIMS Forum 2018, which took place in San Diego last February, the company reported new data on the efficacy of ORY-2001 in animal models for MS, showing that ORY-2001 significantly reduced the clinical score, improved motor activity, reduced inflammatory cell infiltration and improved axonal integrity. In addition to the Phase IIa study in MS, ORY-2001 is currently in another Phase IIa clinical trial, in Alzheimer’s.

Click here to see the full Press Release